MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Hydromorphone (Dilaudid®)

Selected References:

  • Broussard CS, et al. 2011. National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol, 204(4):314.e1–e11.
  • Edwards JE, et al. 2003. Hydromorphone transfer into breast milk after intranasal administration. Pharmacotherapy, 23(2):153-158.
  • Fishman B, et al. 2019. Pregnancy outcome following opioid exposure: a cohort study. PLoS One, 14(7):e0219061.
  • Larson JJ, et al. 2019. Cognitive and behavioral impact on children exposed to opioids during pregnancy. Pediatrics, 144(2): e20190514.
  • Lind JN, et al. 2017. Maternal use of opioids during pregnancy and congenital malformations: a systemic review. Pediatrics, 139(6):e20164131.
  • Rhodes Pharmaceuticals L.P. 2021. Hydromorphone hydrochloride product labeling. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37565441-0d95-4743-a695-d7b3326f58a1.
  • Sinatra RS, et al. 2002. Continuous epidural infusion of 0.05% bupivacaine plus hydromorphone for labor analgesia: an observational assessment in 1830 parturients. Anesth Analg, 94(5):1310-1311.
  • Yazdy MM, et al. 2013. Periconceptional use of opioids and the risk of neural tube defects. ObstetGynecol, 122(4):833-844.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.